Featured Publications
2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients
Forrest JK, Deeb GM, Yakubov SJ, Rovin JD, Mumtaz M, Gada H, O'Hair D, Bajwa T, Sorajja P, Heiser JC, Merhi W, Mangi A, Spriggs DJ, Kleiman NS, Chetcuti SJ, Teirstein PS, Zorn GL, Tadros P, Tchétché D, Resar JR, Walton A, Gleason TG, Ramlawi B, Iskander A, Caputo R, Oh JK, Huang J, Reardon MJ. 2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. Journal Of The American College Of Cardiology 2022, 79: 882-896. PMID: 35241222, DOI: 10.1016/j.jacc.2021.11.062.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEvolut Low Risk trialLow-risk trialsAortic valve replacementPrimary endpointRisk trialsCause mortalityValve replacementTranscatheter Versus Surgical Aortic Valve ReplacementLow surgical risk patientsSurgical aortic valve replacementIndependent clinical events committeeEchocardiographic core laboratoryKaplan-Meier ratesSevere aortic stenosisClinical events committeeLow-risk patientsCause mortality ratesSelf-expanding valvesDisabling strokeEchocardiographic outcomesSurgical AVRTAVR groupSurgery groupAdverse eventsTranscatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Aortic Valves From the STS/ACC TVT Registry
Forrest JK, Kaple RK, Ramlawi B, Gleason TG, Meduri CU, Yakubov SJ, Jilaihawi H, Liu F, Reardon MJ. Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Aortic Valves From the STS/ACC TVT Registry. JACC Cardiovascular Interventions 2020, 13: 1749-1759. PMID: 32473890, DOI: 10.1016/j.jcin.2020.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Valve StenosisBicuspid Aortic Valve DiseaseFemaleHeart Valve ProsthesisHemodynamicsHumansMaleMiddle AgedPostoperative ComplicationsProsthesis DesignRecovery of FunctionRegistriesRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsAortic valve stenosisBicuspid aortic valve stenosisTranscatheter aortic valve replacementEvolut PRO valveAortic valve replacementValve stenosisTVT RegistryCause mortalityValve replacementEvolut RBicuspid valveBicuspid Versus Tricuspid Aortic ValvesSTS/ACC TVT RegistryThoracic Surgeons/American CollegeTricuspid aortic valve stenosisCardiology TVT (Transcatheter Valve Therapy) RegistryTricuspid aortic stenosisRate of strokeSelf-expanding valvesLow complication rateTricuspid aortic valveAcceptable safety outcomesCardiac comorbiditiesEchocardiographic outcomesAortic stenosisEarly Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap
Forrest JK, Mangi AA, Popma JJ, Khabbaz K, Reardon MJ, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL, Brown J, Kipperman R, Saul S, Qiao H, Oh JK, Williams MR. Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. JACC Cardiovascular Interventions 2018, 11: 160-168. PMID: 29348010, DOI: 10.1016/j.jcin.2017.10.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisCause of DeathEchocardiographyFemaleHeart Valve ProsthesisHemodynamicsHumansMaleMitral Valve InsufficiencyPericardiumProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsSelf-expanding transcatheter aortic valveSevere symptomatic aortic stenosisEvolut PRO valveSymptomatic aortic stenosisTranscatheter aortic valveAortic stenosisParavalvular leakAortic valveValve Academic Research Consortium-2 criteriaIndependent echocardiographic core laboratoryTranscatheter aortic valve replacementTranscatheter aortic valve systemEchocardiographic core laboratoryPrimary safety endpointPrimary efficacy endpointRemainder of patientsAortic valve replacementProportion of patientsProsthetic valve regurgitationSupra-annular valveEffective orifice areaDisabling strokeCause mortalityEfficacy endpointSafety endpoint
2024
3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study
Zahr F, Ramlawi B, Reardon M, Deeb G, Yakubov S, Song H, Kleiman N, Chetcuti S, Gada H, Mumtaz M, Leung S, Merhi W, Rovin J, DeFrain M, Muppala M, Kauten J, Rajagopal V, Huang J, Ito S, Forrest J. 3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study. JACC Cardiovascular Interventions 2024, 17: 1667-1675. PMID: 39048253, DOI: 10.1016/j.jcin.2024.05.017.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisBicuspid Aortic Valve DiseaseBioprosthesisFemaleHeart Valve DiseasesHeart Valve ProsthesisHemodynamicsHumansMaleMiddle AgedPostoperative ComplicationsProspective StudiesProsthesis DesignRecovery of FunctionRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsTranscatheter aortic valve replacementRates of all-cause mortalityAll-cause mortalityAortic stenosisThoracic Surgeons Predicted Risk of Mortality scoreThoracic Surgeons Predicted RiskSevere paravalvular aortic regurgitationBicuspid aortic valve anatomyRisk of Mortality scoreEchocardiographic core laboratoryLow-surgical risk patientsAortic valve anatomyKaplan-Meier ratesLow surgical riskClinical events committeeAortic valve replacementSevere aortic stenosisParavalvular aortic regurgitationPermanent pacemaker implantationBicuspid aortic stenosisFavorable hemodynamic performanceEvaluated 3 yearsAttempted implantEchocardiographic outcomesAortic regurgitationReinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis
Grubb K, Lisko J, O'Hair D, Merhi W, Forrest J, Mahoney P, Van Mieghem N, Windecker S, Yakubov S, Williams M, Chetcuti S, Deeb G, Kleiman N, Althouse A, Reardon M. Reinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis. JACC Cardiovascular Interventions 2024, 17: 1007-1016. PMID: 38573257, DOI: 10.1016/j.jcin.2024.01.292.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHumansIncidenceMalePostoperative ComplicationsProsthesis DesignRandomized Controlled Trials as TopicRetreatmentRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementIncidence of reinterventionAortic valve replacementCumulative incidence of reinterventionValve replacementValve reinterventionCumulative incidenceCoreValve transcatheter aortic valve replacementLow incidence of reinterventionSurgical aortic valve replacement patientsSingle-arm studyFirst-generation CoreValveEvolut R/ProParavalvular regurgitationReinterventionRandomized trialsLow incidenceCoreValvePooled dataTranscatheterIncidenceTreatmentYearsEndocarditis
2022
Readmission rates and risk factors for readmission after transcatheter aortic valve replacement in patients with end-stage renal disease
Park DY, An S, Hanna JM, Wang SY, Cruz-Solbes AS, Kochar A, Lowenstern AM, Forrest JK, Ahmad Y, Cleman M, Al Damluji A, Nanna MG. Readmission rates and risk factors for readmission after transcatheter aortic valve replacement in patients with end-stage renal disease. PLOS ONE 2022, 17: e0276394. PMID: 36264931, PMCID: PMC9584363, DOI: 10.1371/journal.pone.0276394.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseTranscatheter aortic valve replacementLength of stayAortic valve replacementIndex hospitalizationHospital mortalityReadmission ratesValve replacementRenal diseaseLonger LOSNational Readmission DatabaseRisk of readmissionChronic pulmonary diseaseMultivariable logistic regressionCardiovascular causesCardiovascular readmissionCause readmissionHospital readmissionPulmonary diseaseHospital chargesPoor outcomeRisk factorsHospital costsReadmissionHigher odds
2021
A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial
Lansky AJ, Makkar R, Nazif T, Messé S, Forrest J, Sharma R, Schofer J, Linke A, Brown D, Dhoble A, Horwitz P, Zang M, DeMarco F, Rajagopal V, Dwyer MG, Zivadinov R, Stella P, Rovin J, Parise H, Kodali S, Baumbach A, Moses J. A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. European Heart Journal 2021, 42: 2670-2679. PMID: 34000004, DOI: 10.1093/eurheartj/ehab213.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEfficacy endpointCerebral embolic protection devicesTranscatheter aortic valve implantationCentral nervous system injuryCerebral embolic lesionsCerebral ischemic lesionsHealth Stroke ScalePrimary efficacy endpointPrimary safety outcomeAortic valve replacementAortic valve implantationEmbolic protection devicesNervous system injuryDiffusion-weighted magnetic resonanceMontreal Cognitive AssessmentEffectiveness endpointCause mortalityCerebral protectionSafety endpointStroke ScaleValve implantationValve replacementI trialIschemic lesionsRandomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement REFLECT II
Nazif TM, Moses J, Sharma R, Dhoble A, Rovin J, Brown D, Horwitz P, Makkar R, Stoler R, Forrest J, Messé S, Dickerman S, Brennan J, Zivadinov R, Dwyer MG, Lansky AJ, Investigators R. Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement REFLECT II. JACC Cardiovascular Interventions 2021, 14: 515-527. PMID: 33663779, DOI: 10.1016/j.jcin.2020.11.011.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementSafety endpointValve replacementProcedure-related ischemic strokeCerebral embolic protectionComposite efficacy endpointPrimary safety endpointCerebral embolizationCerebral protectionEfficacy endpointII trialCerebral injuryIschemic strokeEmbolic protectionPatientsDrug AdministrationUS sitesU.S. FoodEndpointData reviewTrialsMulticenterEmbolizationInjury
2020
Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study
Wyler von Ballmoos MC, Reardon MJ, Williams MR, Mangi AA, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL, Brown J, Kipperman R, Oh JK, Qiao H, Forrest JK. Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study. Cardiovascular Revascularization Medicine 2020, 26: 12-16. PMID: 33199247, DOI: 10.1016/j.carrev.2020.11.007.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEvolut PRO valveParavalvular regurgitationUS clinical studiesCause mortalityClinical studiesNew York Heart Association class ISelf-expanding transcatheter valveValve Academic Research ConsortiumExtreme surgical riskMild paravalvular regurgitationAcademic Research ConsortiumAortic valve replacementIndependent core laboratoryThree-Year OutcomesSelf-expanding prosthesisLong-term resultsEffective orifice areaValve thrombosisCardiovascular mortalityExcellent hemodynamicsValve replacementEchocardiographic measuresSurgical riskTranscatheter valveImpact of Repositioning on Outcomes Following Transcatheter Aortic Valve Replacement With a Self-Expandable Valve
Attizzani GF, Dallan LAP, Markowitz A, Yakubov SJ, Deeb GM, Reardon MJ, Forrest JK, Mangi AA, Huang J, Popma JJ. Impact of Repositioning on Outcomes Following Transcatheter Aortic Valve Replacement With a Self-Expandable Valve. JACC Cardiovascular Interventions 2020, 13: 1816-1824. PMID: 32763073, DOI: 10.1016/j.jcin.2020.04.028.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisFemaleHeart Valve ProsthesisHumansMaleMultidetector Computed TomographyProsthesis DesignRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsEvolut RPrimary outcomeValve Academic Research Consortium-2Academic Research Consortium-2Evolut Low Risk trialPrior percutaneous coronary interventionTranscatheter aortic valve replacementEvolut PRO valveLow-risk trialsThoracic Surgeons scoreAortic valve replacementPercutaneous coronary interventionSelf-expandable valvesTranscatheter aortic valveDisabling strokeEvolut valvesSURTAVI trialCause mortalityTrial patientsCoronary interventionSecondary outcomesSurgeons scoreValve replacementClinical outcomesAortic valveThree Generations of Self-Expanding Transcatheter Aortic Valves A Report From the STS/ACC TVT Registry
Forrest JK, Kaple RK, Tang GHL, Yakubov SJ, Nazif TM, Williams MR, Zhang A, Popma JJ, Reardon MJ. Three Generations of Self-Expanding Transcatheter Aortic Valves A Report From the STS/ACC TVT Registry. JACC Cardiovascular Interventions 2020, 13: 170-179. PMID: 31973793, DOI: 10.1016/j.jcin.2019.08.035.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve InsufficiencyAortic Valve StenosisBioprosthesisFemaleHeart Valve ProsthesisHemodynamicsHumansMaleProsthesis DesignRecovery of FunctionRegistriesRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsEvolut PRO valveTranscatheter aortic valveTVT RegistryAortic regurgitationEvolut RAortic valveSelf-expanding transcatheter aortic valveSTS/ACC TVT RegistryThoracic Surgeons/American CollegeMean aortic valve gradientTranscatheter aortic valve replacement (TAVR) technologyCardiology TVT (Transcatheter Valve Therapy) RegistryTricuspid aortic stenosisAortic valve gradientSignificant aortic regurgitationMild aortic regurgitationSupra-annular valveTranscatheter valve technologyValve gradientHemodynamic statusAortic stenosisAortic annulusEarly outcomesEchocardiographic dataPatient risk
2019
The initial U.S. experience with the Tempo active fixation temporary pacing lead in structural heart interventions
Nazif TM, Chen S, Codner P, Grossman PM, Menees DS, Sanchez CE, Yakubov SJ, White J, Kapadia S, Whisenant BK, Forrest JK, Krishnaswamy A, Arshi A, Orford JL, Leon MB, Dizon JM, Kodali SK, Chetcuti SJ. The initial U.S. experience with the Tempo active fixation temporary pacing lead in structural heart interventions. Catheterization And Cardiovascular Interventions 2019, 95: 1051-1056. PMID: 31478304, DOI: 10.1002/ccd.28476.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCardiac Pacing, ArtificialCardiac Surgical ProceduresEquipment DesignFemaleHeart RateHumansMalePacemaker, ArtificialPatient SafetyPerioperative CareRegistriesRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesVentricular Function, RightConceptsTemporary cardiac pacingTemporary pacing leadStructural heart proceduresPacing leadsHeart proceduresCardiac pacingMulticenter retrospective studyMobilization of patientsRisk of perforationActive fixation mechanismStructural heart interventionsPericardial effusionRetrospective studyLead dislodgmentMean durationPace captureRight ventricleLead stabilitySignificant perforationPatientsHeart interventionsLead performancePacingCapture thresholdPerforation
2018
Trends in volume and risk profiles of patients undergoing isolated surgical and transcatheter aortic valve replacement
Mori M, Bin Mahmood SU, Geirsson A, Yun JJ, Cleman MW, Forrest JK, Mangi AA. Trends in volume and risk profiles of patients undergoing isolated surgical and transcatheter aortic valve replacement. Catheterization And Cardiovascular Interventions 2018, 93: e337-e342. PMID: 30269424, DOI: 10.1002/ccd.27855.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedAged, 80 and overAortic ValveFemaleHeart Valve Prosthesis ImplantationHospitals, High-VolumeHumansMalePatient Reported Outcome MeasuresPractice Patterns, Physicians'Retrospective StudiesRisk AssessmentRisk FactorsTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsSurgical aortic valve replacementAortic valve replacementSTS-PROMSAVR volumeSAVR cohortValve replacementCase volumeTranscatheter aortic valve replacementRisk profileTranscatheter aortic valve replacement (TAVR) programHigh-volume academic medical centerRisk categoriesStudy periodContemporary temporal trendsMedian STS PROMProportion of patientsRisk of mortalityLow-risk categoryAcademic medical centerPROM patientsTAVR cohortTAVR volumeTAVR patientsConsecutive patientsIntermediate riskVentricular septal rupture complicating acute myocardial infarction: Incidence, treatment, and outcomes among medicare beneficiaries 1999–2014
Goldsweig AM, Wang Y, Forrest JK, Cleman MW, Minges KE, Mangi AA, Aronow HD, Krumholz HM, Curtis JP. Ventricular septal rupture complicating acute myocardial infarction: Incidence, treatment, and outcomes among medicare beneficiaries 1999–2014. Catheterization And Cardiovascular Interventions 2018, 92: 1104-1115. PMID: 29513365, DOI: 10.1002/ccd.27576.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionVentricular septal ruptureTimely primary PCIMortality ratePrimary PCIPercutaneous repairSeptal ruptureMyocardial infarctionRetrospective cohort studyUnadjusted mortality ratesUnrepaired patientsVSR repairFatal complicationCohort studyAnnual incidenceMedicare feeService beneficiariesPatientsIncidenceStudy periodMortalityHospitalizationInfarctionRepairPCI
2017
1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses
Deeb GM, Chetcuti SJ, Reardon MJ, Patel HJ, Grossman PM, Schreiber T, Forrest JK, Bajwa TK, O’Hair D, Petrossian G, Robinson N, Katz S, Hartman A, Dauerman HL, Schmoker J, Khabbaz K, Watson DR, Yakubov SJ, Oh JK, Li S, Kleiman NS, Adams DH, Popma JJ. 1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses. JACC Cardiovascular Interventions 2017, 10: 1034-1044. PMID: 28521921, DOI: 10.1016/j.jcin.2017.03.018.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve InsufficiencyAortic Valve StenosisEchocardiographyFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHemodynamicsHumansKaplan-Meier EstimateMaleMiddle AgedProspective StudiesProsthesis FailureQuality of LifeRecovery of FunctionRecurrenceReoperationRisk FactorsTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsSelf-expanding transcatheter aortic valve replacementTranscatheter aortic valve replacementAortic valve replacementMajor stroke rateAortic regurgitationValve replacementStroke rateValve hemodynamicsSevere native aortic valve stenosisSuccessful transcatheter aortic valve replacementNative aortic valve stenosisNew permanent pacemaker implantationSevere residual aortic regurgitationValve prosthesis-patient mismatchMean aortic gradientMean valve gradientResidual aortic regurgitationSevere aortic regurgitationProsthesis-patient mismatchCause mortality ratesIndependent core laboratoryModerate aortic regurgitationPermanent pacemaker implantationAortic valve stenosisAortic valve hemodynamics
2016
Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011)
Arora S, Panaich SS, Patel N, Patel NJ, Lahewala S, Thakkar B, Savani C, Jhamnani S, Singh V, Patel N, Patel S, Sonani R, Patel A, Tripathi B, Deshmukh A, Chothani A, Patel J, Bhatt P, Mohamad T, Remetz MS, Curtis JP, Attaran RR, Mena CI, Schreiber T, Grines C, Cleman M, Forrest JK, Badheka AO. Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011). Catheterization And Cardiovascular Interventions 2016, 88: 605-616. PMID: 26914274, DOI: 10.1002/ccd.26452.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAmputation, SurgicalCross-Sectional StudiesDatabases, FactualDrug CostsEndovascular ProceduresFemaleHospital CostsHospital MortalityHumansLimb SalvageLogistic ModelsLower ExtremityMaleMiddle AgedMultivariate AnalysisOdds RatioPeripheral Arterial DiseasePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPropensity ScoreRisk FactorsTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsGlycoprotein IIb/IIIa inhibitorsPeripheral endovascular interventionsHospital mortalityHospitalization costsEndovascular interventionGPI useAmputation rateUtilization Project Nationwide Inpatient Sample databaseTwo-level hierarchical multivariateIIb/IIIa inhibitorsNationwide Inpatient Sample databaseLower amputation ratesPaucity of dataHospital outcomesPostprocedural complicationsSecondary outcomesPropensity matchingStudy cohortHealthcare costsICD-9Multivariate analysisStudy outcomesSample databaseMortalityHierarchical multivariate
2015
Transcatheter aortic valve replacement versus surgical aortic valve replacement in patients with cirrhosis
Thakkar B, Patel A, Mohamad B, Patel NJ, Bhatt P, Bhimani R, Patel A, Arora S, Savani C, Solanki S, Sonani R, Patel S, Patel N, Deshmukh A, Mohamad T, Grines C, Cleman M, Mangi A, Forrest J, Badheka AO. Transcatheter aortic valve replacement versus surgical aortic valve replacement in patients with cirrhosis. Catheterization And Cardiovascular Interventions 2015, 87: 955-962. PMID: 26699085, DOI: 10.1002/ccd.26345.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisBlood TransfusionCardiac CatheterizationChi-Square DistributionCross-Sectional StudiesDatabases, FactualFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHospital CostsHumansLength of StayLiver CirrhosisLogistic ModelsMaleMiddle AgedMultivariate AnalysisPostoperative ComplicationsPropensity ScoreRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeUnited StatesConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementAortic valve replacementValve replacementNational Inpatient SampleCirrhosis patientsTAVR groupComplication rateICD-9-CM diagnosis codesICD-9-CM procedureHospital mortality rateSevere aortic stenosisHigh-risk patientsOpen heart surgeryYears of agePostprocedural lengthSAVR groupHospital outcomesOperative morbidityPortal hypertensionAortic stenosisCardiac surgeryCardiopulmonary bypassEsophageal varicesLiver cirrhosisIntravascular Ultrasound in Lower Extremity Peripheral Vascular Interventions
Panaich SS, Arora S, Patel N, Patel NJ, Savani C, Patel A, Thakkar B, Singh V, Patel S, Patel N, Agnihotri K, Bhatt P, Deshmukh A, Gupta V, Attaran RR, Mena CI, Grines CL, Cleman M, Forrest JK, Badheka AO. Intravascular Ultrasound in Lower Extremity Peripheral Vascular Interventions. Journal Of Endovascular Therapy 2015, 23: 65-75. PMID: 26637836, DOI: 10.1177/1526602815620780.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAmputation, SurgicalChi-Square DistributionCost-Benefit AnalysisDatabases, FactualEndovascular ProceduresFemaleHospital CostsHospital MortalityHumansLimb SalvageLinear ModelsLower ExtremityMaleMiddle AgedMultivariate AnalysisOdds RatioPeripheral Vascular DiseasesPractice Patterns, Physicians'Risk FactorsTime FactorsTreatment OutcomeUltrasonography, InterventionalUnited StatesYoung AdultConceptsLower limb endovascular interventionsPostprocedural complicationsHospitalization costsEndovascular interventionHospital mortalityAmputation rateOdds ratioNonsignificant increaseUtilization Project Nationwide Inpatient Sample databaseTwo-level hierarchical multivariateICD-9 procedure codesNationwide Inpatient Sample databasePeripheral vascular proceduresCo-primary outcomesLower amputation ratesPeripheral vascular interventionsPeripheral endovascular interventionsConfidence intervalsIVUS useIVUS utilizationSecondary outcomesStudy cohortVascular proceduresVascular interventionsHealthcare costsMechanical Circulatory Support Devices and Transcatheter Aortic Valve Implantation (from the National Inpatient Sample)
Singh V, Patel SV, Savani C, Patel NJ, Patel N, Arora S, Panaich SS, Deshmukh A, Cleman M, Mangi A, Forrest JK, Badheka AO. Mechanical Circulatory Support Devices and Transcatheter Aortic Valve Implantation (from the National Inpatient Sample). The American Journal Of Cardiology 2015, 116: 1574-1580. PMID: 26434512, DOI: 10.1016/j.amjcard.2015.08.020.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationMechanical circulatory support devicesAortic valve implantationCirculatory support devicesMCS devicesValve implantationHigh-risk surgical patientsPropensity score-matched analysisClinical Modification procedure codesSupport devicesVentricular fibrillation arrestNationwide Inpatient SampleCost of hospitalizationShort-term useSignificant increaseUnacceptably high ratesInhospital mortalityInhospital outcomesCardiogenic shockIndependent predictorsSurgical patientsNinth RevisionTAVI procedureTransapical accessInpatient SampleVariability in utilization of drug eluting stents in United States: Insights from nationwide inpatient sample
Panaich SS, Badheka AO, Arora S, Patel NJ, Thakkar B, Patel N, Singh V, Chothani A, Deshmukh A, Agnihotri K, Jhamnani S, Lahewala S, Manvar S, Panchal V, Patel A, Patel N, Bhatt P, Savani C, Patel J, Savani GT, Solanki S, Patel S, Kaki A, Mohamad T, Elder M, Kondur A, Cleman M, Forrest JK, Schreiber T, Grines C. Variability in utilization of drug eluting stents in United States: Insights from nationwide inpatient sample. Catheterization And Cardiovascular Interventions 2015, 87: 23-33. PMID: 26032938, DOI: 10.1002/ccd.25977.Peer-Reviewed Original Research